Literature DB >> 12669766

Search of antimicrobial activity of selected non-antibiotic drugs.

Hanna Kruszewska1, Tomasz Zareba, Stefan Tyski.   

Abstract

A variety of pharmaceutical preparations, which are applied in the management of non-infectious diseases, have shown in vitro some antimicrobial activity. These drugs are called "non-antibiotics". The aim of this study was to detect and characterise the antimicrobial activity of non-antibiotic drugs. selected from the preparations analysed during state control performed at the Drug Institute in Poland. Over 160 pharmaceutical preparations were randomly chosen from different groups of drugs. The surveillance study was performed on standard ATCC microbial strains used for drug control: S aureus, E. coil, P. aeruginosa and C. albicans. It was shown that the drugs listed below inhibited growth of at least one of the examined strains:acyclovir (Awirol 5%, cream), alendronate (Alenato 5 mg, tabl.), alverine (Meteospasmyl 20 mg, caps.), butorphanole (Butamidor 10 mg/ml, amp.), clodronate (Sindronat 400 mg, caps), diclofenac (Olfen 75 mg, amp.), emadastine (Emadine 0.05%, eye dr.), etodolac (Febret 200 mg, caps.), fluvastatine (Lescol 40 mg, tabl.), ketamine (Ketamidor 10%, amp.), levocabastine (Histimet 0.5 mg/ml, eye dr.), losartan (Lorista 50 mg, tabl.), matipranolol (Betaman 0.3% eye dr.), mesalazine (Pentasa 1%, susp.), naproxen (Nalgesin 550 mg, tabl.), oxaprosine (Reumax 600 mg, tabl.), oxymethazoline (Nasivin 0.025%, nose dr.), proxymetacaine (Alcaine 0.5%, eye dr.), ribavirin (Rebetol 200 mg, caps.), rutoside with ascorbic acid (Cerutin 20+200 mg, tabl.), sulodexide (Vessel due F, 250 LSU, caps.), tegaserole (Zelmac 50 mg, tabl.), telmisartan (Pritor 20 mg, tabl.), temosolomide (Temodal 100 mg, caps.), ticlopidine (Ticlid 250 mg, tabl.), tolfenamic acid (Migea rapid 200 mg, tabl.), tramadole (Tramundin 100 mg, tabl.), tropicamide (Tropicamidum 1%, eye dr.). Staphylococcus aureus was susceptible to most of the drugs listed above. Ticlopidine showed activity against S. aureus, E. coli and C. albicans (MICs equal to: 0.45; 0.45 and 0.65 mg/ml, respectively). Oxymetazoline showed activity against S. aureus and E. coli (MICs: 0.005 and 0.025 mg/ml, respectively). Pseudomonas aeruginosa was sensitive to alendronate, clondronate, oxaprozine, ribavirin and tramadole (MICs: 10, 63, 60, 3 and 43 mg/ml, respectively).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12669766

Source DB:  PubMed          Journal:  Acta Pol Pharm        ISSN: 0001-6837            Impact factor:   0.330


  19 in total

Review 1.  Antimicrobial Effects of Antipyretics.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 2.  Drug-gut microbiota interactions: implications for neuropharmacology.

Authors:  Jacinta Walsh; Brendan T Griffin; Gerard Clarke; Niall P Hyland
Journal:  Br J Pharmacol       Date:  2018-06-28       Impact factor: 8.739

Review 3.  A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders.

Authors:  Shokufeh Ghasemian Sorboni; Hanieh Shakeri Moghaddam; Reza Jafarzadeh-Esfehani; Saman Soleimanpour
Journal:  Clin Microbiol Rev       Date:  2022-01-05       Impact factor: 26.132

4.  Effect of thioridazine on experimental cutaneous staphylococcal infections.

Authors:  Beth L Hahn; Peter G Sohnle
Journal:  In Vivo       Date:  2014 Jan-Feb       Impact factor: 2.155

5.  Pharmacological exploitation of an off-target antibacterial effect of the cyclooxygenase-2 inhibitor celecoxib against Francisella tularensis.

Authors:  Hao-Chieh Chiu; Jian Yang; Shilpa Soni; Samuel K Kulp; John S Gunn; Larry S Schlesinger; Ching-Shih Chen
Journal:  Antimicrob Agents Chemother       Date:  2009-04-27       Impact factor: 5.191

6.  Gut microbes in neurocognitive and mental health disorders.

Authors:  Tyler Halverson; Kannayiram Alagiakrishnan
Journal:  Ann Med       Date:  2020-08-31       Impact factor: 4.709

7.  Association Between Bisphosphonates and Hospitalized Clostridioides difficile Infection Among Frail Older Adults.

Authors:  Kevin W McConeghy; Andrew R Zullo; Christine W Lary; Tingting Zhang; Yoojin Lee; Lori Daiello; Douglas P Kiel; Sarah Berry
Journal:  J Am Med Dir Assoc       Date:  2020-01-10       Impact factor: 4.669

Review 8.  Drug repurposing for the treatment of staphylococcal infections.

Authors:  Shankar Thangamani; Haroon Mohammad; Waleed Younis; Mohamed N Seleem
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

9.  Clinically Relevant Growth Conditions Alter Acinetobacter baumannii Antibiotic Susceptibility and Promote Identification of Novel Antibacterial Agents.

Authors:  Jennifer M Colquhoun; Rachel A F Wozniak; Paul M Dunman
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

10.  Probiotic mixture VSL#3 reduce high fat diet induced vascular inflammation and atherosclerosis in ApoE(-/-) mice.

Authors:  Yee Kwan Chan; Hani El-Nezami; Yan Chen; Kristiina Kinnunen; Pirkka V Kirjavainen
Journal:  AMB Express       Date:  2016-08-30       Impact factor: 3.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.